Merck & Co., Inc. (MRK) has faced a 15% year-to-date stock market decline, attributed to challenges with its GARDASIL vaccine in China. Jim Cramer has expressed confidence in the company’s robust portfolio to overcome setbacks, including possible antitrust concerns related to the Verona acquisition.

Cramer highlighted Merck & Co., Inc. (MRK)’s $50 billion new drug pipeline, alleviating concerns about the Keytruda patent expiration in 2028. He praised the potential of a novel compound for COPD treatment and emphasized the company’s strategic acquisitions to drive growth in the pharmaceutical sector.

Despite Merck & Co., Inc. (MRK)’s investment potential, some believe that AI stocks offer higher returns with limited downside risk. Investors seeking opportunities in the AI sector can explore potential options that align with market trends and government policies to maximize profitability.

For more insights on stock market trends, check out articles on stocks projected to double in three years and hidden AI stocks with growth potential. Stay informed about market opportunities and emerging trends to make well-informed investment decisions.

Read more at Yahoo Finance: Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer